A 42-year-old man with bipolar II disorder has been on lithium 800 mg daily for 18 months. Routine blood work shows: serum lithium 0.9 mEq/L (therapeutic), serum creatinine 1.4 mg/dL (baseline 0.8 mg/dL), fasting glucose 128 mg/dL (normal <100), TSH 6.2 mIU/L (normal 0.4–4.0), and free T4 is low-normal. Urinalysis shows specific gravity 1.005 (normal 1.010–1.030). The patient reports polyuria and polydipsia for the past 6 months. What is the most likely chronic adverse effect of lithium in this patient?

Explanation

## Chronic Lithium Adverse Effects ### Clinical Presentation Analysis **Key Point:** This patient shows the classic triad of chronic lithium toxicity: 1. **Polyuria + polydipsia** → diabetes insipidus (DI) phenotype 2. **Low urine specific gravity (1.005)** → inability to concentrate urine 3. **Progressive renal dysfunction** → rising creatinine despite therapeutic lithium level ### Nephrogenic Diabetes Insipidus (NDI) ```mermaid flowchart TD A[Chronic Lithium Exposure]:::outcome --> B[Lithium accumulation in collecting duct]:::action B --> C[Inhibits adenylyl cyclase & cAMP signaling]:::action C --> D[Impaired aquaporin-2 water channel insertion]:::action D --> E[Loss of ADH responsiveness]:::action E --> F[Nephrogenic DI: polyuria + polydipsia]:::outcome F --> G[Chronic dehydration & volume depletion]:::action G --> H[Progressive renal fibrosis & CKD]:::urgent ``` ### Pathophysiology of Lithium-Induced NDI | Mechanism | Effect | Timeline | |-----------|--------|----------| | **ADH receptor antagonism** | Blocks V2 receptor signaling in collecting duct | Acute (days–weeks) | | **cAMP inhibition** | Reduces aquaporin-2 expression and trafficking | Chronic (months–years) | | **Tubular damage** | Chronic interstitial fibrosis, atrophy of collecting duct | Years (irreversible) | | **Urine concentration defect** | Inability to produce concentrated urine; polyuria 1–3 L/day | Persistent | **Clinical Pearl:** Lithium-induced NDI is **irreversible** in ~50% of patients even after lithium discontinuation. Early detection (as in this case) is critical to prevent progression to ESRD. ### Why This Patient Has NDI 1. **Polyuria + polydipsia** for 6 months → chronic symptom pattern 2. **Low urine specific gravity (1.005)** → inability to concentrate urine (normal >1.010) 3. **Rising creatinine (0.8 → 1.4 mg/dL)** → progressive renal impairment 4. **Therapeutic lithium level (0.9 mEq/L)** → toxicity occurs even within "therapeutic range" with chronic exposure 5. **18 months of exposure** → sufficient time for chronic tubular damage **High-Yield:** Lithium-induced NDI occurs in 20–40% of long-term users. It is the most common renal complication of lithium therapy and can progress to chronic kidney disease (CKD) stage 3–4 if unrecognized. ### Management 1. **Assess renal function:** eGFR, 24-hour creatinine clearance 2. **Confirm NDI:** Water deprivation test (if needed) — urine osmolality remains <300 mOsm/kg despite ADH administration 3. **Options:** - **Discontinue lithium** if possible (consider alternative mood stabilizer: valproate, lamotrigine, atypical antipsychotic) - **If lithium essential:** Use lowest effective dose, maintain euvolemia, monitor renal function every 6 months - **Symptomatic relief:** NSAIDs (indomethacin) or thiazide diuretics (paradoxically reduce polyuria by promoting proximal tubular reabsorption) ### Why Other Options Are Wrong **Hypothyroidism:** While lithium does cause hypothyroidism (TSH elevation in 20–30% of patients), this patient's TSH is only mildly elevated (6.2) with low-normal T4. Hypothyroidism does NOT cause polyuria or low urine specific gravity. Hyperglycemia is not a direct effect of lithium-induced hypothyroidism. **Acute interstitial nephritis:** This is an acute process (days–weeks) with fever, rash, eosinophilia. This patient has a chronic presentation (6 months) with progressive renal dysfunction and NDI phenotype. **Hyperthyroidism:** Lithium causes hypothyroidism, not hyperthyroidism. Thyroid storm is not a lithium adverse effect.